Niagen Bioscience collaborates with USP to establish USP monograph

Niagen Bioscience (NAGE) announces that Nicotinamide Riboside Chloride, NRCI, the patented form of nicotinamide riboside in the Company’s flagship ingredient, Niagen, now has a published United States Pharmacopeia, USP, dietary supplement ingredient monograph. Rob Fried, Chief Executive Officer of Niagen Bioscience, said, “This monograph is a meaningful development for the broader NAD+ supplement industry because NR now has a published pharmacopeial standard, while NMN and NAD+ do not. It underscores the importance of doing the long-term scientific and technical work required to help define a quality standard.”